All In Biotech

Free tool

FAERS Monitor: Focalin Xr

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 021802 or its brand name (Focalin Xr, Dexmethylphenidate Hydrochloride). Reports on generic versions are filed under their own applications.

Reports

4,283

Serious

1,583

37% of reports

Hospitalization

406

Death reported

36

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective769
  • nausea206
  • anxiety199
  • headache188
  • fatigue176
  • abnormal behaviour168
  • feeling abnormal167
  • decreased appetite160
  • disturbance in attention158
  • off label use150
  • insomnia147
  • aggression144
  • depression141
  • vomiting141
  • dizziness130

Reports by year received

View as table
YearReports
200414
200531
200678
200782
200882
200983
201082
2011114
2012125
2013116
2014149
2015394
2016420
2017313
2018245
2019277
2020242
2021177
2022244
2023303
2024263
2025258
2026191

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,049,876 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
abnormal behaviourSignal16820.918.03,158
disturbance in attentionSignal15814.412.41,960
aggressionSignal14414.212.11,748
anxietySignal1993.43.0346
feeling abnormalSignal1673.43.0287
decreased appetiteSignal1603.42.9269
depressionSignal1413.02.6194
drug ineffectiveSignal7692.92.7995
insomniaSignal1472.72.3159
vomiting1411.51.321
headache1881.51.329
dizziness1301.31.18
nausea2061.31.113
fatigue1761.11.02
off label use1500.80.75

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.